The mission of the Georgetown Lombardi Comprehensive Cancer Center (LCCC) is to prevent, treat and cure cancers by linking scientific discovery, expert and compassionate patient care, quality education, and partnership with the community, guided by the principle of cura personalis (care for the whole person). LCCC is led by Director Louis M. Weiner, MD, a medical oncologist and immunotherapy expert, with the support of Deputy Director Michael B. Atkins, MD, six Associate Directors (ADs) and Sandra M. Swain, LCCC's clinical network representative. Four Research Programs?Breast Cancer, Cancer Prevention and Control, Experimental Therapeutics and Molecular Oncology?conduct high-impact studies supported by nine Shared Resources. LCCC has 91 members, with a current annual total of $28.7M in peer-reviewed ($18.5M NCI) cancer-focused funding (direct costs), resulting in 1,100 peer-reviewed cancer-related publications from 2009-2012; 32% of which involved intra- and/or interprogrammatic collaborations, and 53% of which involved external collaborations. In 2012, LCCC placed 244 patients on interventional clinical trials (13% of new patients). Notable accomplishments include: 1) discovery of a transformative methodology for epithelial cell reprogramming with rapid translation into clinical trials; 2) development of enabling tools such as novel computational modeling for drug repurposing and integrated informatic platforms; 3) basic discovery (novel mechanisms for genomic instability; transcriptional targeting in Ewing sarcoma; resistance determinants in the EGFR network); 4) leadership of high-impact clinical trials (e.g., evaluation of pertuzumab in breast cancer, role of bendamustine in follicular lymphoma); 5) national collaborative modeling research informing screening mammography guidelines and 6) operational enhancements that include creation of the MedStar Georgetown Cancer Network to expand clinical research in LCCC's catchment area under the direction of recent recruit, Giuseppe Giaccone, MD, PhD (AD, Clinical Research); a reorganization of clinical trial management and regulatory activities to better support the Network; and the continued development of community outreach and research sites in the poorest wards of the District of Columbia.

Public Health Relevance

The vision of the Georgetown Lombardi Comprehensive Cancer Center (LCCC) is to prevent and cure cancer with a local focus and global impact. This is achieved through basic, translational, dinical and population-directed research that addresses important causes and consequences of cancer. LCCC is the only NCI-designated comprehensive cancer center based in the nation's capital.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA051008-25S1
Application #
9617457
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-08-15
Project End
2019-04-30
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
25
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Georgetown University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Smith, Jill P; Wang, Shangzi; Nadella, Sandeep et al. (2018) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother 67:195-207
Edwardson, Matthew A; Zhong, Xiaogang; Fiandaca, Massimo S et al. (2018) Plasma microRNA markers of upper limb recovery following human stroke. Sci Rep 8:12558
Kaat, Aaron J; Schalet, Benjamin D; Rutsohn, Joshua et al. (2018) Physical function metric over measure: An illustration with the Patient-Reported Outcomes Measurement Information System (PROMIS) and the Functional Assessment of Cancer Therapy (FACT). Cancer 124:153-160
Maximov, Philipp Y; Abderrahman, Balkees; Fanning, Sean W et al. (2018) Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer. Mol Pharmacol 94:812-822
Czarnecka, Magdalena; Lu, Congyi; Pons, Jennifer et al. (2018) Neuropeptide Y receptor interactions regulate its mitogenic activity. Neuropeptides :
Gonzalez, Thomas L; Moos, Rebecca K; Gersch, Christina L et al. (2018) Metabolites of n-Butylparaben and iso-Butylparaben Exhibit Estrogenic Properties in MCF-7 and T47D Human Breast Cancer Cell Lines. Toxicol Sci 164:50-59
Pannkuk, Evan L; Laiakis, Evagelia C; Fornace Jr, Albert J et al. (2018) A Metabolomic Serum Signature from Nonhuman Primates Treated with a Radiation Countermeasure, Gamma-tocotrienol, and Exposed to Ionizing Radiation. Health Phys 115:3-11
Singh, Zeba N; Duong, Vu H; Koka, Rima et al. (2018) High-Risk Acute Promyelocytic Leukemia with Unusual T/Myeloid Immunophenotype Successfully Treated with ATRA and Arsenic Trioxide-Based Regimen. J Hematop 11:67-74
Fan, Ping; Tyagi, Amit K; Agboke, Fadeke A et al. (2018) Modulation of nuclear factor-kappa B activation by the endoplasmic reticulum stress sensor PERK to mediate estrogen-induced apoptosis in breast cancer cells. Cell Death Discov 4:15
da Cruz, Raquel Santana; Carney, Elissa J; Clarke, Johan et al. (2018) Paternal malnutrition programs breast cancer risk and tumor metabolism in offspring. Breast Cancer Res 20:99

Showing the most recent 10 out of 1120 publications